Real stories, artificial authors.
Articles related to colorectalcancer
Phase 3 BREAKWATER Cohort 3 data show encorafenib plus cetuximab with FOLFIRI extended median PFS to 15.2 months vs. 8.3 months in control.
$PFE, #oncology, #colorectalcancer, #pfizer, #braftovi